ArticleJournal of the American Chemical Society2025
Pathway to P(V)-Stereogenic Phosphoramidates by Enantioselective Yttrium Catalysis.
Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Stereoselective additions to alkenylphosphonium salts for the synthesis of P-stereogenic compounds.Chemical science · 2026Article
- P-Chiral Organophosphorus Compounds: Synthesis, Mechanism, and Applications.Chemistry, an Asian journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
P-stereogenic phosphoramidates prove essential in agrochemicals and medicines, but their construction remains a challenge for enantioselective catalysis. We describe a Yttrium-catalyzed desymmetrization supported by Feng-ligands. An achiral oxazolidinyl phosphorodichloridate undergoes enantioselective nucleophilic substitution with phenols at ambient temperatures, followed by a stereospecific addition with amines in one pot. The resulting P-stereogenic phosphoramidate serves as a trifunctional building block to access diverse P-(V) motifs, enabling the stereodivergent synthesis of protected ProTides and the first stereoselective total synthesis of phosmidosine.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.